News | October 24, 2025
Laurus Labs posts Q2 FY26 consolidated PAT higher at Rs. 195 Cr
Laurus Labs has reported total income of Rs. 1,680.43 crore during the period ended September 30, 2025
Laurus Labs has reported total income of Rs. 1,680.43 crore during the period ended September 30, 2025
Nicardipine Hydrochloride in 0.9% Sodium Chloride Injection is indicated for the short-term treatment of hypertension when oral therapy is not feasible or desirable
Vaccine efficacy against primary CMV infection ranged from 6 per cent to 23 per cent, depending on case definition, falling short of Moderna’s predefined target
The acquisition centers on ImCheck’s lead Phase I/II program, ICT01, a first-in-class monoclonal antibody targeting BTN3A
Takeda will make an upfront payment of $1.2 billion, which includes a $100 million equity investment in Innovent
The submissions are supported by data from the Phase 3 KEYNOTE-905 trial
Results from the Phase 2 PHAROS trial potentially establish new benchmark with targeted combination therapies for this patient population
RPG Life Sciences has reported total income of Rs. 186.22 crore during the period ended September 30, 2025
Contera Pharma will receive an upfront payment and full research funding for each target under investigation
Vamikibart is the first targeted, non-steroid treatment designed to address the underlying inflammation driving UME
Subscribe To Our Newsletter & Stay Updated
